BiomX Inc. (PHGE) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarter ended June 30, 2025. BiomX Inc. is a clinical-stage biotechnology company developing phage-based therapies for chronic bacterial infections, primarily focusing on Cystic Fibrosis (CF) and Diabetic Foot Osteomyelitis (DFO). The company operates as a single segment and is headquartered in Ness Ziona, Israel. Following a 1-for-10 reverse stock split effective August 2024, the company had approximately 26.5 million shares of common stock outstanding as of August 11, 2025.
Key Financial Metrics
| Metric (USD in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(6,037) | $(4,471) | $(13,696) | $(12,856) |
| Operating Loss | $(7,433) | $(9,725) | $(15,189) | $(16,510) |
| R&D Expenses (Net) | $(5,014) | $(6,897) | $(10,264) | $(11,002) |
| G&A Expenses | $(2,419) | $(2,828) | $(4,925) | $(5,508) |
| Cash & Equivalents (End of Period) | $14,046 | N/A | $14,046 | N/A |
| Total Cash & Restricted Cash | $15,186 | N/A | $15,186 | N/A |
| Net Cash Used in Operating Activities | N/A | N/A | $(14,821) | $(22,593) |
| Net Cash Provided by Financing Activities | N/A | N/A | $11,884 | $38,772 |
Note: The company has no revenue. Expenses are net of government grants received from the Israel Innovation Authority (IIA) and the Medical Technology Enterprise Consortium (MTEC).
Material Changes vs. Prior Period
- Operating Expenses: Operating loss decreased by approximately 24% in Q2 2025 compared to Q2 2024 ($7.4M vs $9.7M). This reduction was driven by decreased salaries due to workforce reductions, lower rent expenses following a 2024 right-of-use asset impairment, and higher grant receipts ($1.0M in Q2 2025 vs $0.8M in Q2 2024).
- Non-Operating Income: Income from the change in fair value of warrants decreased significantly to $1.5M in Q2 2025 from $11.9M in Q2 2024. This reduction is attributed to the revaluation of warrant liabilities.
- Debt: Interest expense was negligible in 2025 ($5k for Q2) compared to 2024, as the company prepaid its entire Hercules Capital loan balance in March 2024.
- Capital Structure: The company completed a "February 2025 Financing" (SPA) raising approximately $5.5M in gross proceeds and an inducement agreement raising $6.5M, significantly increasing the weighted average shares outstanding.
Guidance, Outlook, and Risks
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. Current cash resources ($15.2M) are projected to fund operations only into the first quarter of 2026. Additional financing will be required.
- Clinical Progress:
- BX004 (Cystic Fibrosis): Initiated a Phase 2b study in July 2025; topline results expected in Q1 2026.
- BX211 (Diabetic Foot Osteomyelitis): Announced positive Phase 2 results in March 2025 showing statistically significant wound healing. A potential registrational study is planned pending FDA feedback and funding.
- Geopolitical Risks: The company faces significant risks due to ongoing conflicts in the Middle East (Israel, Iran, Gaza, Lebanon). While operations have not been materially impacted to date, escalation could disrupt business, delay trials, or hinder capital raising.
- Regulatory & Development: Risks include the ability to enroll patients, obtain FDA acceptance of non-U.S. trials, and the unpredictable timing/cost of phage therapy development.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $15.2M cash balance to fund the Phase 2b trial and operations through Q1 2026 without immediate dilution.
- Financing Terms: Review the specific terms of the February 2025 SPA and Inducement Letter Agreements, particularly the exercise prices ($0.9306) and the liability classification of warrants which impacts net income volatility.
- Grant Dependency: Assess the sustainability of R&D funding given the reliance on IIA and MTEC grants, which are recorded as expense reductions rather than revenue.
- Geopolitical Exposure: Evaluate the contingency plans for the company's Israel-based headquarters and manufacturing in the event of regional escalation.
- Warrant Liability: Monitor the fair value of outstanding warrants (classified as liabilities), as fluctuations in stock price will directly impact reported net loss.